[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-to-severe-plaque-psoriasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-to-severe-plaque-psoriasis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,41,79,113,146,169,192,214,236,256,276],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644685","phase-3-a-multicenter-randomized-double-blind-placebo-controlled-phase--study-to-evaluate-the-efficacy-and-safety-of-wd-890-tablets-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-100644685",false,"NCT07672561","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent.\n* Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.\n* Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization\n\nExclusion Criteria:\n\n* Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.)\n* Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted\n* Class III or IV congestive heart failure by New York Heart Association Criteria",true,"ALL","18 Years","75 Years",{"count":20,"type":21},375,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.",[27],"Moderate to Severe Plaque Psoriasis","RECRUITING","2026-06-26",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":32},"2026-03-18",{"date":36,"type":21},"2027-07-30",{"name":38,"class":39},"Zhejiang Wenda Pharma Technology LTD.","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100548788","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-bimekizumab-compared-to-ustekinumab-in-children-and-adolescents-from-6-years-to-less-than-18-years-of-age-with-moderate-to-severe-plaque-psoriasis-100548788","NCT06425549","A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis","BE TOGETHER","Inclusion Criteria:\n\n* Study participant must be 6 to \\\u003C18 years of age, inclusive, at the time of signing the informed consent\u002Fassent according to local regulation\n* Study participant has had a diagnosis of moderate to severe plaque psoriasis (PSO) for at least 3 months prior to the Screening Visit\n* Study participant meets the following at both the Screening and Baseline Visits:\n\n  1. Body surface area (BSA) affected by PSO ≥10%\n  2. . Investigator's Global Assessment (IGA) score ≥3 (on a scale from 0 to 4)\n  3. . Psoriasis Area and Severity Index (PASI) score ≥12 OR\n\nPASI score ≥10 plus at least 1 of the following:\n\ni) Clinically relevant facial involvement ii) Clinically relevant genital involvement iii) Clinically relevant hand and foot involvement\n\n* Study participant is a candidate for systemic PSO therapy and\u002For photo\u002Fchemotherapy and for treatment with ustekinumab per labeling\n* Study participant has body weight ≥15 kg and body mass index for age percentile of ≥5 at Screening\n\nExclusion Criteria:\n\n* Primary failure (no response within 12 weeks) to 1 or more interleukin-17 (IL-17) biologic response modifiers (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 biologic response modifier other than an IL-17\n* Study participant has a presence of guttate, inverse, pustular, or erythrodermic PSO or other dermatological condition that may impact the clinical assessment of PSO\n* Study participant has a history of inflammatory bowel disease (IBD) or symptoms suggestive of IBD\n* History of active tuberculosis unless successfully treated, latent TB unless prophylactically treated\n* Study participant has an active infection or history of infections (such as serious infection, chronic infections, opportunistic infections, unusually severe infections)\n* Study participant has previously received bimekizumab\n* Study participant has previously received ustekinumab\n* Study participant has received drugs outside the specified timeframes relative to the Baseline Visit or receives prohibited concomitant treatments\n* Study participant has the presence of active suicidal ideation, or positive suicide behavior\n* Study participant diagnosed with severe depression in the past 6 months (prior to Screening) should be excluded\n* Study participant has a history of psychiatric inpatient hospitalization within the past year before enrolling into the study","6 Years","17 Years",{"count":52,"type":21},168,[24],"The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \\\u003C18 years of age with moderate to severe plaque psoriasis (PSO).",[27],[57,58,59,60,61,62,63,64,65,66,67],"bimekizumab","BKZ","ustekinumab","paediatric study participants","children","adolescents","Psoriasis","PSO","Plaque Psoriasis","Paediatric Psoriasis","Pediatric Psoriasis","2026-05-21",{"date":70,"type":32},"2026-05-22",{"date":72,"type":32},"2024-06-25",{"date":74,"type":21},"2030-11-08",{"name":76,"class":77},"UCB Biopharma SRL","INDUSTRY",50,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":87,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100584350","phase-1-a-study-to-assess-the-concentration-of-bimekizumab-in-mature-breast-milk-from-mothers-receiving-treatment-with-bimzelx-bimekizumab-100584350","NCT06888193","A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)","A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)","BE CARING","Inclusion Criteria:\n\n* Study participant must be at least 18 years of age at the time of signing the informed consent.\n* Study participant is being treated with commercial bimekizumab per locally approved prescribing information and in accordance with her treating physician.\n* Study participant is breastfeeding and intends to breastfeed throughout the Sampling Period.\n* The decision to treat with bimekizumab and to breastfeed is made independently from and prior to the study participant consenting to participate in the study.\n* Study participant must be on bimekizumab treatment for at least 12 weeks after delivery and since starting\u002Frestarting\u002Fcontinuing bimekizumab prior to sampling (prior to start of the Sampling Period).\n* A female study participant is eligible to participate if she is not pregnant and does not plan to become pregnant during the study.\n\nExclusion Criteria:\n\n* Study participant has any medical, obstetrical, or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.\n* The infant has any abnormality noted on physical examination or medical history that, in the opinion of the Investigator, may jeopardize or compromise study participation.\n* Study participant has a history of chronic alcohol or drug abuse within the previous last year.\n* Study participant has history of breast implants, breast augmentation, or breast reduction surgery.\n* Study participant plans a surgical intervention during the Screening Period and Sampling Period or anticipates having surgery while participating in the Sampling Period (does not apply to tubal ligation).\n* Study participant or her infant has participated in another study of an investigational medicinal product (IMP) (and\u002For an investigational device) within the previous 6 months or is currently participating in another study of an IMP (and\u002For an investigational device), unless the study is UCB PS0036 or a bimekizumab registry study.\n* Study participant or her infant has previously participated (ie, entered the sampling period) in this study.","FEMALE",{"count":89,"type":21},20,[91],"PHASE1","Primary purpose of the study is to assess the concentration of bimekizumab in mature human breast milk.",[27,94,95,96],"Psoriatic Arthritis","Axial Spondyloarthritis","Hidradenitis Suppurativa",[98,99,100,64,101,102,103],"Bimekizumab","Breastfeeding mothers","Bimzelx®","HS","AxSpa","PsA","2026-04-30",{"date":106,"type":32},"2026-05-01",{"date":108,"type":32},"2025-11-05",{"date":110,"type":21},"2027-05-03",{"name":76,"class":77},12,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":40},"100630291","phase-4-metformin-combined-with-secukinumab-for-moderate-to-severe-plaque-psoriasis-in-overweight-or-obese-chinese-patients-100630291","NCT07485764","Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Metformin in Combination With Secukinumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients","Inclusion Criteria:\n\n1. Subjects voluntarily participate in the study and sign the informed consent form.\n2. Aged 18-75 years (inclusive) at the time of signing informed consent, male or female.\n3. Diagnosed with chronic plaque psoriasis for \\>=6 months prior to the first study drug administration.\n4. Overweight\u002Fobesity: Body mass index (BMI) \\>=25 kg\u002Fm².\n5. Moderate-to-severe plaque psoriasis (defined as):\n\n   Psoriasis Area and Severity Index (PASI) score \\>=12 at screening and prior to first dose.\n\n   Investigator's Global Assessment (IGA) score \\>=3 at screening and prior to first dose.\n\n   Stable disease within 2 months prior to randomization.\n6. Deemed candidates for phototherapy or systemic therapy by the investigator, defined as subjects with moderate-to-severe chronic plaque psoriasis uncontrolled by:\n\n   Topical therapy and\u002For phototherapy and\u002For prior systemic therapy.\n7. Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study medication (Day 0). Both women of childbearing potential and male patients with reproductive capacity must agree to use highly effective contraceptive methods during the study and for 15 weeks following the last dose.\n8. Lactating women agree to discontinue breastfeeding during the study and for 15 weeks following the last dose of study medication.\n9. Subjects must be capable of effective communication with investigators and adhere to the clinical trial protocol to complete all study requirements. -\n\nExclusion Criteria:\n\n* 1: BMI \\\u003C25 kg\u002Fm². 2: Presence of guttate, pustular, or erythrodermic psoriasis, or other diseases that may confound treatment outcomes (e.g., cutaneous lesions, systemic autoimmune diseases).\n\n  3: Drug-induced psoriasis (e.g., new-onset or exacerbated psoriasis caused by beta-blockers, calcium channel blockers, or lithium).\n\n  4: Use of prohibited medications: Systemic non-biologic agents (e.g., glucocorticoids, leflunomide, methotrexate, cyclosporine, retinoids, azathioprine, mycophenolate mofetil, traditional Chinese medicines for psoriasis) within 4 weeks prior to screening.\n\nEtanercept or its biosimilars within 4 weeks prior to screening; TNF-α inhibitors or their biosimilars within 12 weeks prior to screening.\n\nOther biologic agents for psoriasis (e.g., IL-12\u002F23 or IL-23 inhibitors) within 5 half-lives of the drug prior to screening.\n\n5: Prior use of secukinumab or other IL-17A\u002FIL-17R-targeted biologic agents within 12 weeks prior to screening.\n\n6: History of malignancy within the past 5 years (e.g., cutaneous squamous cell carcinoma, basal cell carcinoma, cervical carcinoma in situ).\n\n7: Active inflammatory diseases other than psoriasis that may confound the evaluation of secukinumab efficacy.\n\n8: Metabolic or inflammatory diseases (e.g., type 2 diabetes) that may confound the evaluation of metformin efficacy.\n\n9: History of lymphoproliferative disorders (e.g., lymphoma, lymphadenopathy) or splenomegaly.\n\n10: Opportunistic infections within 6 months prior to screening (e.g., herpes zoster, CMV, Mycoplasma, Pneumocystis jirovecii, histoplasmosis, candidiasis, aspergillosis, NTM).\n\n11: Chronic or recurrent infectious diseases (e.g., chronic hepatitis, pyelonephritis) or severe\u002Flife-threatening infections within 6 months prior to screening; current signs\u002Fsymptoms suggestive of infection (e.g., fever, cough, dysuria, abdominal pain, diarrhea, infected skin wounds).\n\n12: High risk of infection (e.g., leg ulcers, indwelling urinary catheters, recurrent chest infections, bedridden\u002Fwheelchair-bound status).\n\n13: Major surgery within 8 weeks prior to screening or planned during the study, deemed to pose unacceptable risk by the investigator.\n\n14: Live virus\u002Fbacterial vaccines (e.g., BCG) within 6 weeks prior to screening or planned during the study\u002Fwithin 15 weeks after last dose.\n\n15: Participation in another clinical trial within 4 weeks prior to screening or within 5 half-lives of the investigational product (whichever is longer).\n\n16: Laboratory abnormalities: Hemoglobin \\\u003C8.5 g\u002FdL WBC \\\u003C2,500\u002FμL ANC \\\u003C1,500\u002FμL Platelets \\\u003C100,000\u002FμL ALT\u002FAST \\>2×ULN Creatinine \\>176.8 μmol\u002FL (2.0 mg\u002FdL) 17: Active hepatitis B (positive HBsAg). 18: Positive HCV antibody. 19: HIV infection or positive HIV antibody. 20: Syphilis infection. 21: Active or latent tuberculosis at screening. 22: Hypersensitivity to trial drug excipients, murine\u002Fhuman proteins, or immunoglobulin products.\n\n23: Inability to communicate\u002Fcomply (e.g., psychiatric disorders, frequent travel, lack of motivation).\n\n24: Other conditions deemed by the investigator to compromise study participation.",{"count":121,"type":21},186,[123],"PHASE4","This is a randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in China. The study aims to evaluate the efficacy and safety of metformin combined with secukinumab in the treatment of moderate-to-severe plaque psoriasis in overweight or obese Chinese patients.\n\nA total of approximately 186 participants will be enrolled and randomly assigned in a 1:1 ratio to receive either secukinumab plus metformin or secukinumab plus placebo. The study consists of a screening period, an induction period, a maintenance period, and a follow-up period, with a total duration of 60 weeks.\n\nThe primary endpoints are the proportions of participants achieving PASI75 (≥75% improvement in Psoriasis Area and Severity Index) and an IGA score of 0 or 1 (clear or almost clear) at Week 24. Secondary endpoints include PASI90, quality of life (DLQI), pruritus NRS score, metabolic parameters, and safety assessments.\n\nThis study aims to provide a more effective combination therapy for psoriasis patients with overweight or obesity.",[63,65,126,127],"Moderate-to-severe Plaque Psoriasis","Overweight , Obesity",[129,130,131,132,133,134,135],"Metformin","Secukinumab","IL-17 Inhibitor","Randomized Controlled Trial","Double-Blind","Placebo-Controlled","Chinese Patients","NOT_YET_RECRUITING","2026-03-22",{"date":139,"type":32},"2026-03-25",{"date":141,"type":21},"2026-06",{"date":143,"type":21},"2029-06",{"name":145,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100626224","phase-2-a-clinical-study-evaluating-the-efficacy-and-safety-of-cms-d001-tablets-in-the-treatment-of-adult-patients-with-moderate-to-severe-plaque-type-psoriasis-100626224","NCT07432854","A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ\u002FⅢ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Aged 18-75 years, willing to sign the ICF\n* Diagnosed with plaque psoriasis for at least 6 months prior to screening.\n* At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3\n* Be eligible for phototherapy or systemic therapy.\n\nExclusion Criteria:\n\n* Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline.\n* Other skin diseases at screening or baseline Drug-induced psoriasis.\n* History of severe herpes zoster or severe herpes simplex or current herpes simplex\u002Fzoster infection.\n* History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose.\n* History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose.\n* Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks.\n* Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol.\n* History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation.\n* History of malignant tumour within 5 years before screening.\n* Previous or current autoimmune diseases.\n* Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.\n* Allergic to any component of the investigational drug.",{"count":154,"type":21},540,[156,24],"PHASE2","This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II\u002FIII operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.",[27],"2026-02-24",{"date":161,"type":32},"2026-02-25",{"date":163,"type":21},"2026-03-03",{"date":165,"type":21},"2028-07-30",{"name":167,"class":77},"Dermavon Holdings Limited",21,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":22,"phases":179,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":40},"100610977","a-study-to-evaluate-effectiveness-and-safety-of-a-tyk2-inhibitor-in-subjects-with-moderate-to-severe-plaque-psoriasis-100610977","NCT07234591","A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis","A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Male and female, ages 18 to 70 years\n* Body weight \\>40 kg, body mass index (BMI) of 18 to 40 kg\u002Fm2\n* Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit\n* Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.\n\nExclusion Criteria:\n\n* Diagnosed with non-plaque psoriasis\n* Previously received tyrosine kinase 2 (TYK2) inhibitors\n* Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects\n* Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;\n* Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.\n* Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;\n* Other conditions that the investigator deems unsuitable for participation in this study.\n\nOther protocol defined inclusion\u002Fexclusion criteria could apply","70 Years",{"count":178,"type":21},140,[180],"NA","A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks",[65,27],"2025-11-14",{"date":185,"type":32},"2025-11-18",{"date":187,"type":32},"2025-10-21",{"date":189,"type":21},"2026-05-30",{"name":191,"class":77},"Usynova Pharmaceuticals Ltd.",{"id":193,"slug":194,"hasResults":11,"nctId":195,"briefTitle":196,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":199,"targetDuration":201,"studyType":202,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100569605","phase-iv-study-vunakizumab-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis-100569605","NCT06696417","Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis","A Prospective, Single-arm, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Vunakizumab in Adults With Moderate-to-severe Plaque Psoriasis Who Have Not Previously Received Biologics","Inclusion Criteria:\n\n* Age ≥18 years old at the time of signing the informed consent, regardless of gender;\n* Moderate to severe plaque psoriasis was diagnosed;\n* Plan to receive vunakizumab therapy as assessed by the investigator;\n* The subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study; Patients voluntarily sign informed consent forms.\n\nExclusion Criteria:\n\n* Previous treatment with biological agents: including but not limited to anti-tumor necrosis factor-α (TNF-α), anti-IL-17, anti-IL-17 receptor, anti-IL-12 \u002FIL-23 or IL-23p19 antibody drugs;\n* Severe hypersensitivity to vunakizumab active ingredient or any excipients;\n* Patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors;\n* Fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after last receiving the study drug;\n* Any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.",{"count":200,"type":21},1516,"60 Weeks","OBSERVATIONAL","This is a multicenter, prospective, observational study of 1516 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of vunakizumab in patients with moderate-to-severe chronic plaque psoriasis. Approximately 50-100 clinical trial centers are planned to participate in the study. The study consisted of a 7-day screening period, a 52-week treatment period and an 8-week safety follow-up period.\n\nThe recommended dose of vunakizumab is 240 mg (120 mg in two injections), with subcutaneous injection at week 0, 2, and 4, followed by a dose every 4 weeks and a final injection at week 48 (the actual treatment regimen is based on the clinician's recommendation). After the corresponding assessment at 52 weeks, an 8-week safety follow-up period was entered until the end of the study.",[27],"2025-05-12",{"date":207,"type":32},"2025-05-14",{"date":209,"type":32},"2025-02-17",{"date":211,"type":21},"2028-04",{"name":213,"class":39},"First Hospital of China Medical University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":22,"phases":224,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":4},"100588634","phase-3-a-phase-iii-study-of-syhx1901-tablets-in-the-treatment-of-moderate-to-severe-plaque-psoriasis-100588634","NCT06943950","A Phase III Study of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis","A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis","Inclusion Criteria:\n\nSubjects fully understand and voluntarily participate in this study and sign informed consent; 2. Age ≥18 and ≤ 65 years old; 3. Subjects with a clinical diagnosis of stable moderate-to-severe plaque psoriasis with a history ≥6 months before randomization; Subjects with stable moderate-to-severe plaque psoriasis defined as meeting all four of the following criteria simultaneously:\n\n1. Subject must be diagnosed of chronic plaque psoriasis with no morphological changes or significant outbreaks of disease activity assessed by the investigator;\n2. Subject must be a candidate for systemic treatment or phototherapy assessed by the investigator;\n3. Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% at screening and baseline;\n4. PASI score of ≥10 and Static Physician's Global Assessment (sPGA) score ≥3 at screening and baseline; 4. Negative blood pregnancy results should be provided 7 days (inclusive) prior to randomization, and subjects and their partners should voluntarily take contraceptive measures considered effective by the investigator during the study period and for at least 28 days after the study; 5. Subjects must be volunteer and be able to complete study procedures and follow-up examinations.\n\nExclusion Criteria:\n\n1. Forms of psoriasis other than plaque psoriasis (Guttate psoriasis、erythrodermic psoriasis、Pustular psoriasis、Drug-induced psoriasis);\n2. Previous or current autoimmune disease that may affect the clinical evaluation of psoriasis;\n3. Other active skin conditions that may affect the clinical evaluation of psoriasis;\n4. Active bacterial, viral, fungal, or other infection that requires medical intervention;\n5. With progressive or uncontrolled systemic disease, or with chronic disease identified by the investigator as inappropriate for participation in the study;\n6. History of malignancy ;\n7. Any other medical and\u002For social reasons identified by the investigator as inappropriate for participation in the study;","65 Years",{"count":223,"type":21},500,[24],"The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis.",[27],"2025-04-27",{"date":229,"type":32},"2025-04-30",{"date":231,"type":21},"2025-06-01",{"date":233,"type":21},"2027-06-30",{"name":235,"class":77},"CSPC Ouyi Pharmaceutical Co., Ltd.",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":254,"locationsCount":4},"100581014","phase-3-a-study-of-hs-20137-in-participants-with-moderate-to-severe-plaque-psoriasis-100581014","NCT06844799","A Study of HS-20137 in Participants with Moderate-to-severe Plaque Psoriasis","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate Efficacy and Safety of HS-20137, an Anti-IL-23 Monoclonal Antibody, in Participants with Moderate-to-severe Plaque Psoriasis","Inclusion Criteria:\n\n1. Adults aged 18 and above, male or female;\n2. Diagnosed plaque psoriasis for at least 6 months before randomization, with or without psoriatic arthritis;\n3. During screening and randomization, the severity of plaque psoriasis was moderate to severe, and the following conditions should be met: a) BSA≥10%; b) PASI≥12; c) sPGA≥3;\n4. Suitable for systemic therapy or phototherapy;\n5. Voluntarily participate in the research, have the ability and willingness to complete the research according to the research protocol, and sign the informed consent.\n\nExclusion Criteria:\n\n1. Previous use of biological agents, or allergic reactions to known drug ingredients, or previous severe food or drug allergies;\n2. Confirmation of other types of psoriasis, including but not limited to guttiform psoriasis, pustular psoriasis, erythrodermic psoriasis, drug-induced exacerbation of psoriasis (including beta-blockers, non-steroidal anti-inflammatory drugs, antimalarial drugs, interferon, calcium channel blockers, or lithium induced psoriasis) from the screening period to the time before randomization;\n3. Other skin lesions, chronic inflammatory diseases or autoimmune diseases, including but not limited to systemic lupus erythematosus, Sjogren's syndrome, skin sclerosis, etc., assessed by the investigator and other factors that may affect the efficacy evaluation or assessed by other researchers before randomization;\n4. Primary treatment failure occurred with previous use of similar investigatory drugs (including marketed ulinumab, gusecciumab, Tiricizumab, Lisenciumab, and IL-23 target investigatory drugs under development) (the minimum treatment standard was not reached 12 weeks after the first treatment);\n5. Use of the following drugs before randomization:\n\n   1. Use of topical treatment drugs that affect the evaluation of psoriasis within 2 weeks before randomization;\n   2. 4 weeks before randomization, Use of phototherapy, traditional systemic therapy drugs, small molecule targeted drugs that may affect the evaluation of psoriasis;\n   3. use of TNF-α biologics within 3 months prior to randomization;\n   4. use of other biologics for the treatment of psoriasis within 6 months before randomization; e) Use of oral or topical proprietary Chinese medicinesor other Chinese herbal medicines that affect or may affect the evaluation of psoriasis within 4 weeks prior to randomization;\n\n   f) use of lymphocyte migration regulators or B cell and T cell regulators within 3 months before randomization, or 6 months before screening, (whichever is older) use of B-cell-specific scavenging drugs;\n6. A history of chronic recurrent infection, or opportunistic infection in the 6 months prior to screening, or hospitalization for a serious infectious disease or intravenous antibiotic use in the 2 months prior to randomization, with a confirmed or suspected illness in the 1 week prior to randomization. And Other circumstances determined by the investigator to be unsuitable for further study participation.",{"count":244,"type":21},720,[24],"The primary objective of this study is to evaluate the efficacy and safety of HS-20137 in the treatment of participants with moderate to severe plaque psoriasis.",[126],"2025-02-19",{"date":250,"type":32},"2025-02-25",{"date":252,"type":21},"2025-06-10",{"date":233,"type":21},{"name":255,"class":77},"Hansoh BioMedical R&D Company",{"id":257,"slug":258,"hasResults":11,"nctId":259,"briefTitle":196,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":22,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":136,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":40},"100575962","phase-4-phase-iv-study-vunakizumab-efficacy-and-safety-in-moderate-to-severe-plaque-psoriasis-100575962","NCT06779097","A Prospective, Single-arm, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Vunakizumab in Adults With Moderate-to-severe Plaque Psoriasis Who Have Converted From Other Biologics","Inclusion Criteria:\n\n1. Age ≥18 years old at the time of signing the informed consent, regardless of gender;\n2. Diagnosed with moderate to severe plaque psoriasis;\n3. The subject voluntarily signs informed consent before the start of any procedures related to the study, can communicate with the researcher smoothly, understands and is willing to strictly comply with the requirements of this clinical study protocol to complete the study;\n4. Patients who have been treated with biologics for ≥12 weeks prior to screening and are in line with the biologics conversion recommendations of the Chinese Guidelines for the Treatment of Psoriasis Biologics and Small Molecule Drugs (2024 edition), and who have been screened and evaluated by researchers as eligible for biologics therapy.\n\nExclusion Criteria:\n\n1. Patients previously treated with IL-17A inhibitors (IL-17Ai) had primary failure;\n2. Patients who had previously used IL-17A inhibitors (IL-17Ai) and experienced drug-related adverse events leading to drug withdrawal;\n3. Patients with severe hypersensitivity to the active ingredient or any excipients of Vunakizumab;\n4. Fertile women (defined as all women with physical conditions necessary for pregnancy) and men who are pregnant or unwilling or unable to use highly effective birth control during the study period and within 20 weeks after the last receipt of the study drug;\n5. Patients with clinically important active diseases, such as active tuberculosis, active hepatitis, and active malignant tumors;\n6. Any other circumstances that the investigator believes will prevent the subject from following and completing the study protocol.",{"count":263,"type":21},1564,[123],"This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque psoriasis who have converted from other biologics. To explore the efficacy of difficult-to-treat area, patient satisfaction and patient-reported outcomes (PRO).",[27],"2025-01-14",{"date":269,"type":32},"2025-01-16",{"date":271,"type":21},"2025-02",{"date":273,"type":21},"2028-02",{"name":275,"class":77},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.",{"id":277,"slug":278,"hasResults":11,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":283,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":202,"phases":4,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100535964","real-world-safety-and-effectiveness-of-sotyktu-deucravacitinib-in-patients-with-moderate-to-severe-plaque-psoriasis-in-korea-100535964","NCT06258668","Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea","Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis","Inclusion Criteria:\n\n* Adult participants ≥19 years of age\n* Diagnosis of moderate-to-severe plaque psoriasis\n* Candidate for phototherapy or systemic therapy\n* Will begin deucravacitinib according to approved product label\n\nExclusion Criteria:\n\n* Participants prescribed deucravacitinib for therapeutic indications not approved in Korea\n* Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)","19 Years",{"count":285,"type":21},505,"The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.",[126],"2024-11-05",{"date":290,"type":32},"2024-11-06",{"date":292,"type":32},"2024-08-21",{"date":294,"type":21},"2028-09-30",{"name":296,"class":77},"Bristol-Myers Squibb",2]